Clinical Trial Detail

NCT ID NCT01670877
Title Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Washington University School of Medicine
Indications

Her2-receptor negative breast cancer

Therapies

Neratinib

Age Groups: adult

Additional content available in CKB BOOST